Intranasal vaccination is an interesting and increasingly attractive alternative to improving the delivery of therapeutic vaccines. It comes with the promise of better efficacy by stimulating local mucosal response, needle-free delivery and could be self-administrable. These qualities present several opportunities for future immunizations but there are still several challenges to overcome in their development and future commercialization.
In this webinar, we will review and share insights on success factors in developing an intranasal vaccine, and provide an overview of intranasal formulations and formulation strategies for both liquid and powder administration. We will also assess the available options for intranasal device platforms, review nasal deposition models and discuss the latest intranasal vaccine manufacturing needs from development to commercial scale.
Key Learning Objectives
- Advantages of mucosal vaccines
- Overview of intranasal vaccine formulations
- Discuss intranasal vaccine opportunities and challenges
- Highlight vaccine device offerings at Aptar Pharma
